|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...8283848586878889909192...9899» |
- |||| Envarsus (LCP-Tacro) / Asahi Kasei
Trial completion: Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients (clinicaltrials.gov) - Jul 2, 2012
P2, N=58, Completed, Sponsor: Veloxis Pharmaceuticals
Enrolling by invitation --> Completed
- ||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion: A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects (clinicaltrials.gov) - Jul 2, 2012
P1, N=64, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Enrolling by invitation --> Completed Recruiting --> Completed
- Trial initiation date: TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding (clinicaltrials.gov) - Jul 1, 2012
P=N/A, N=120, Recruiting, Sponsor: Fourth Military Medical University
Recruiting --> Completed Initiation date: Sep 2011 --> Jul 2012
- Enrollment open: TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding (clinicaltrials.gov) - Jul 1, 2012
P=N/A, N=120, Recruiting, Sponsor: Fourth Military Medical University
Initiation date: Sep 2011 --> Jul 2012 Not yet recruiting --> Recruiting
- | Amnolake (tamibarotene) / Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma
Trial completion, Metastases: Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jun 28, 2012
P1/2, N=43, Completed, Sponsor: Zeria Pharmaceutical
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P3 trial: Type2 HRS: TYPE 2 HEPATORENAL SYNDROME (clinicaltrials.gov) - Jun 27, 2012
P3, N=46, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
- Clinical: MR-Guided Laser Ablation of Hepatic Tumors (clinicaltrials.gov) - Jun 26, 2012
P0, N=22, Recruiting, Sponsor: Mayo Clinic
- | INX 189 / BMS, Daklinza (daclatasvir) / BMS
New P2 trial: Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jun 26, 2012
P2, N=360, Suspended, Sponsor: Bristol-Myers Squibb
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P1 trial: A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - Jun 26, 2012
P1, N=44, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
- faldaprevir (BI201335) / Boehringer Ingelheim
Trial completion: Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment (clinicaltrials.gov) - Jun 26, 2012
P1, N=32, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver (clinicaltrials.gov) - Jun 25, 2012
P2, N=32, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed N=60 --> 32
- preladenant (SCH 420814) / Merck (MSD)
Trial completion: A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) (clinicaltrials.gov) - Jun 25, 2012
P1, N=42, Completed, Sponsor: Merck
N=60 --> 32 Recruiting --> Completed
- Trial completion: PSE: Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=50, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver (clinicaltrials.gov) - Jun 25, 2012
P2, N=32, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed Recruiting --> Completed
- ||||| New P2 trial: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Na (clinicaltrials.gov) - Jun 24, 2012
P2, N=110, Completed, Sponsor: Hoffmann-La Roche
- Trial completion, FDG PET: Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects (clinicaltrials.gov) - Jun 24, 2012
P=N/A, N=13, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Recruiting --> Completed
- sunitinib / Generic mfg.
Trial completion, Surgery: SAKK 77/06: Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 24, 2012
P2, N=45, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P4 trial: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (clinicaltrials.gov) - Jun 21, 2012
P4, N=98, Recruiting, Sponsor: Taichung Veterans General Hospital
- ||||| Engerix-B (hepatitis B vaccine recombinant) / GSK
New P4 trial: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix (clinicaltrials.gov) - Jun 21, 2012
P4, N=667, Completed, Sponsor: GlaxoSmithKline
- |||||||||| New P3 trial: Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies (clinicaltrials.gov) - Jun 19, 2012
P3, N=600, Active, not recruiting, Sponsor: Gilead Sciences
- Clinical: Optimization of Antiviral Therapy of Chronic HBV Infection (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=67, Completed, Sponsor: Changhai Hospital
- | cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver (clinicaltrials.gov) - Jun 18, 2012
P2, N=47, Active, not recruiting, Sponsor: ImClone LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| entecavir / Generic mfg.
Enrollment closed: A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection (clinicaltrials.gov) - Jun 17, 2012
P1/2, N=64, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE) (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=10, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting Recruiting --> Completed
- Engerix-B (hepatitis B vaccine recombinant) / GSK
Enrollment change: Observational Study of Immune Response to Hepatitis B Childhood Booster (clinicaltrials.gov) - Jun 14, 2012
P=N/A, N=28, Completed, Sponsor: University of Oxford
Recruiting --> Completed N=50 --> 28
- Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion: Observational Study of Immune Response to Hepatitis B Childhood Booster (clinicaltrials.gov) - Jun 14, 2012
P=N/A, N=28, Completed, Sponsor: University of Oxford
N=50 --> 28 Enrolling by invitation --> Completed
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New P2 trial: A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers (clinicaltrials.gov) - Jun 14, 2012
P2, N=32, Completed, Sponsor: Novartis Pharmaceuticals
- Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion, Adherence: UFO VAX: A Randomized Trial of Vaccine Adherence in Young Injection Drug Users (clinicaltrials.gov) - Jun 13, 2012
P=N/A, N=546, Completed, Sponsor: University of California, San Francisco
Enrolling by invitation --> Completed Recruiting --> Completed
- Clinical: Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=50, Recruiting, Sponsor: University of Chicago
- Clinical: A2ALL-2: Adult-to-Adult Living Donor Transplant Cohort Study (clinicaltrials.gov) - Jun 12, 2012
P=N/A, N=1900, Recruiting, Sponsor: Beth Golden
- pravastatin / Generic mfg., sorafenib / Generic mfg.
Enrollment open: PRODIGE 21t: Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis (clinicaltrials.gov) - Jun 12, 2012
P2, N=160, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Not yet recruiting --> Recruiting
- ornithine phenylacetate oral (MNK-6106) / Mallinckrodt
Trial initiation date: STOP-ALF: Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury (clinicaltrials.gov) - Jun 11, 2012
P2, N=24, Recruiting, Sponsor: William Lee
Not yet recruiting --> Recruiting Initiation date: Mar 2012 --> Jun 2012
- ornithine phenylacetate oral (MNK-6106) / Mallinckrodt
Enrollment open: STOP-ALF: Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury (clinicaltrials.gov) - Jun 11, 2012
P2, N=24, Recruiting, Sponsor: William Lee
Initiation date: Mar 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- | Cystaran (cysteamine) / Leadiant Biosciences
Trial completion: A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jun 11, 2012
P1/2, N=13, Completed, Sponsor: Joel Lavine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- sorafenib / Generic mfg.
New P1 trial: Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 11, 2012
P1, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
- |||||||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University, Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: PRINCIPAL: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (clinicaltrials.gov) - Jun 7, 2012
P3, N=880, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- Trial initiation date, Metastases: Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis (clinicaltrials.gov) - Jun 6, 2012
P1/2, N=20, Recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Active, not recruiting --> Completed Initiation date: Mar 2011 --> Jun 2012
- ||| GS-0938 / Gilead
Enrollment change: QUANTUM: Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (clinicaltrials.gov) - Jun 6, 2012
P2, N=239, Completed, Sponsor: Gilead Sciences
Initiation date: Mar 2011 --> Jun 2012 N=450 --> 239
- Neocarzinostatin (zinostatin) / Astellas
Trial withdrawal: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Albert Koong
N=450 --> 239 Recruiting --> Withdrawn
- GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment change: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Jun 6, 2012
P1, N=24, Completed, Sponsor: Gilead Sciences
Recruiting --> Withdrawn N=48 --> 24
- | GSK 2336805 / J&J
Enrollment change, Combination therapy: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects (clinicaltrials.gov) - Jun 6, 2012
P2, N=17, Completed, Sponsor: GlaxoSmithKline
N=48 --> 24 N=32 --> 17
- Neocarzinostatin (zinostatin) / Astellas
Enrollment change: Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2012
P3, N=0, Withdrawn, Sponsor: Albert Koong
N=32 --> 17 N=120 --> 0
- New P2 trial: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Jun 6, 2012
P2, N=10, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- | GS-0938 / Gilead, Sovaldi (sofosbuvir) / Gilead
Trial completion: Open-Label Hepatic Impairment Study (clinicaltrials.gov) - Jun 6, 2012
P1, N=24, Completed, Sponsor: Gilead Sciences
N=120 --> 0 Recruiting --> Completed
- | GSK 2336805 / J&J
Trial completion, Combination therapy: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects (clinicaltrials.gov) - Jun 6, 2012
P2, N=17, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer
Trial completion, Metastases: Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2012
P2, N=20, Completed, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Recruiting --> Completed Active, not recruiting --> Completed
- sorafenib / Generic mfg.
Trial termination, Combination therapy, Metastases: SOCRATES: TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jun 5, 2012
P2, N=43, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- sorafenib / Generic mfg.
Trial initiation date, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - Jun 5, 2012
P2, N=40, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Terminated Initiation date: Nov 2011 --> Jun 2012
- sorafenib / Generic mfg.
Enrollment change, Combination therapy, Metastases: SOCRATES: TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jun 5, 2012
P2, N=43, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Initiation date: Nov 2011 --> Jun 2012 N=72 --> 43
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial completion: A PK and Safety Study in Subjects With Hepatic Impairment (clinicaltrials.gov) - Jun 5, 2012
P1, N=32, Completed, Sponsor: Trius Therapeutics, Inc.
N=72 --> 43 Recruiting --> Completed